Aker BioMarine Misses Q2 Estimates as Ingredient Sales Rise, Profits Fall

Aker BioMarine reported a 5% year-over-year increase in second-quarter revenue, though both top-line results and profitability fell short of analyst expectations. The Norway-based supplier of krill-derived health products announced Friday that its performance was bolstered by strong demand in its ingredients business, while its consumer division faced challenges.

Q2 Performance Details

The company's financial results for the quarter showed a mixed performance, missing consensus estimates.

• Revenue: Reached $57.90 million, a 5% increase from the prior-year period but below the $60 million consensus estimate from one analyst.
• Adjusted EBITDA: Fell 4% year-over-year to $12.90 million, missing the $14 million estimate from two analysts.

Segment Breakdown

The company's two main business units showed divergent results. The Human Health Ingredients segment was a key growth driver, with revenue climbing 17% year-over-year. Aker BioMarine attributed this to solid krill oil volume growth and a greater proportion of higher-value capsulated oil sales. However, the segment's EBITDA margin declined slightly due to increased investments in sales and marketing.

Ad

In contrast, the Consumer Health Products segment experienced headwinds from lower sales through major U.S. retail chains. The company also cited an ongoing marketing repositioning at its Epion brand as a factor impacting performance.

Outlook and Strategic Review

Looking ahead, Aker BioMarine said it anticipates continued year-over-year growth and improved profits for its Human Health Ingredients segment. The company also expects its Consumer Health Products segment to return to modest growth.

Significantly, Aker BioMarine is exploring strategic alternatives for its high-performing Human Health Ingredients unit. The company stated it aims to complete a transaction related to this review sometime in 2026.